HitGen and BioAge Launch Phase I Study of BGE‑102, a Novel NLRP3 Inhibitor
China‑based HitGen Inc. (SHA: 688222) announced that its partner, BioAge Labs, Inc. (NASDAQ: BIOA), has...
HitGen
HitGen’s 2025 H1 Report Shows 16.58% Revenue Growth and 391% Profit Surge
China-based HitGen Inc. (SHA: 688222) on Aug 27, 2025 released its semi‑annual financial results for...
HitGen Inc. Initiates Phase II Clinical Trial for HG146 in Adenoid Cystic Carcinoma
China-based HitGen Inc. (SHA: 688222) has announced the commencement of the first patient enrollment in...
HitGen Inc. Partners with Ablink Biotech to Develop Antibody-Oligonucleotide Conjugates
China-based HitGen Inc. (SHA: 688222) has entered into a partnership with compatriot firm Ablink Biotech...
HitGen Secures Strategic Partnerships to Enhance Drug Discovery for Startups
China-based HitGen Inc. (SHA: 688222) has announced strategic partnerships with LabCentral, a prominent life science...
HitGen Secures CDE Approval for Lipisense IND Filing, Advancing Development for Dyslipidemia Treatment
HitGen Inc., (SHA: 688222) a China-based pharmaceutical company, has announced that the Investigational New Drug...
HitGen’s Vernalis Partners with Hox Therapeutics to Develop Novel Cancer Inhibitors
HitGen Inc. (SHA: 688222), based in China, announced that its wholly owned subsidiary Vernalis (R&D)...
HitGen Inc. and Bostal Drug Delivery Form Strategic Partnership to Advance Nucleic Acid Drug Development
HitGen Inc. (SHA: 688222), a China-based company, has announced a strategic partnership with Bostal Drug...
Panlin Capital Raises Second Fund Focused on Biopharmaceutical Innovation
Panlin Capital has announced the successful closing of its second venture capital fund, the Hangzhou...
Canada’s SGC Partners with HitGen to Enhance Drug Discovery Using DEL Technology
The Structural Genomics Consortium (SGC) of Canada has announced a strategic partnership with China-based HitGen...
HitGen Inc. Partners with Nested Therapeutics for Precision Medicine Research
China-based HitGen Inc. (SHA: 688222) has announced a research service agreement with Cambridge, Massachusetts-based precision...
HitGen Inc. Enters Research Agreement with ARase Therapeutics to Discover Oncology Inhibitors
China-based HitGen Inc. (SHA: 688222) has announced a research agreement with ARase Therapeutics, Inc. Under...
HitGen and Nitrase Therapeutics Enter Research Agreement
China-based HitGen Inc. (SHA: 688222) announced a research agreement with US firm Nitrase Therapeutics, Inc....
HitGen Partners with Guangzhou AIChemEco for Automated Synthesis Technology
China-based HitGen Inc. (SHA: 688222) has announced a partnership with compatriot firm Guangzhou AIChemEco. The...
HitGen Partners with Daewoong Pharmaceutical for Drug Discovery
China-based HitGen Inc. (SHA: 688222) has announced a research collaboration agreement with South Korea’s Daewoong...
HitGen Partners with C4X Discovery to Identify Novel Inflammatory Disease Treatments
China-based HitGen Inc. (SHA: 688222) has announced a partnership with UK-headquartered C4X Discovery Holdings plc...
HitGen’s Vernalis Subsidiary Collaborates with Unison Medicines on Undruggable Bacterial Target
China’s HitGen Inc. (SHA: 688222) announced a strategic research collaboration between its wholly owned subsidiary,...
HitGen and LoQus23 Therapeutics Partner on DNA Encoded Library for Neurodegeneration
China-based HitGen Inc. (SHA: 688222) announced a strategic partnership with UK-headquartered LoQus23 Therapeutics Ltd, leveraging...
HitGen and Haichang Bio Partner to Develop Anti-Cancer RNAi Drugs
China-based HitGen Inc. (SHA: 688222) announced the establishment of a strategic partnership with compatriot firm...
HitGen Inc. Forms Strategic Partnership for New Drug Research and Development
China-based HitGen Inc. (SHA: 688222) announced the establishment of a strategic partnership with compatriot firm...